No Data
No Data
Goldman Sachs: Maintain JD HEALTH's "Buy" rating, raising the Target Price to HKD 36.7.
Goldman Sachs released a Research Report stating that it maintains a "Buy" rating for JD HEALTH (06618), raising the Target Price from 33.5 Hong Kong dollars to 36.7 Hong Kong dollars. The bank holds a constructive view on JD HEALTH's leading position in the online pharmacy sector, especially as its market share in drug categories continues to capture from peers and offline retailers. Recent profit margins may be impacted by the higher investments, including on-demand delivery and offline pharmacy construction, as well as AI plans surrounding the Medical vertical model. The report mentioned that JD HEALTH has reserved an additional investment of 3 to 0.5 billion yuan for this year, with rapid revenue growth and an improvement in gross margin.
OpenAI Secures Near-$12 Billion CoreWeave Deal, Taking Stake In Cloud Firm Ahead Of $35 Billion IPO To Reportedly Reduce Microsoft Dependence
Goldman Sachs stated that hedge funds have reduced their exposure to Stocks at the largest scale in over two years.
Goldman Sachs stated in a report on Monday that hedge funds closed individual Stocks last Friday at the largest scale in over two years, with some activities comparable to March 2020, when portfolio managers reduced market exposure during the pandemic. The major stock indices in the USA plummeted last Friday, with the Nasdaq Index falling by 4%, as concerns grew that Trump's tariff policies could push the USA, the world's largest economy, into recession. "This is a typical de-leveraging crisis," said James Koutoulas, CEO of hedge fund Typhon Capital Management. Goldman Sachs noted in the report that
Everbright Futures: The risk aversion sentiment has significantly increased on "Black Monday," and Gold may face adjustments in the short term.
On March 10, COMEX Gold fell at the end of trading, closing at $2893.3 per ounce, a decrease of 0.71%. The domestic SHFE Gold night market opened low and continued to decline, closing at 676.24 yuan per gram, down 0.53%. Signals of economic slowdown are increasing, and the latest consumer expectations survey from the New York Fed shows that short-term inflation expectations in the USA rose in February, while medium- to long-term inflation expectations remained stable, with consumers increasingly concerned about their financial situation. Goldman Sachs has lowered its growth forecast for the USA and pointed out that the impact of the current round of tariff escalation is broader, and rising inflation may lead to a decline in consumers' actual income, making spending more cautious, potentially hindering economic growth.
Express News | Couche-Tard: Goldman Sachs, Royal Bank of Canada, and Scotiabank Have Provided Highly Confident Letters in Support of Our Financing
Express News | Goldman Sachs' Managing Director in Derivatives Sale and Macro Execution Team Scott Rubner Has Left-Source